Boceprevir for HCV in patients with HIV: where next?
Publication
, Journal Article
Osinusi, A; Naggie, S
Published in: Lancet Infect Dis
July 2013
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Infect Dis
DOI
EISSN
1474-4457
Publication Date
July 2013
Volume
13
Issue
7
Start / End Page
563 / 564
Location
United States
Related Subject Headings
- Ribavirin
- Recombinant Proteins
- Proline
- Polyethylene Glycols
- Microbiology
- Male
- Interferon-alpha
- Interferon alpha-2
- Humans
- Hepatitis C, Chronic
Citation
APA
Chicago
ICMJE
MLA
NLM
Osinusi, A., & Naggie, S. (2013). Boceprevir for HCV in patients with HIV: where next? Lancet Infect Dis, 13(7), 563–564. https://doi.org/10.1016/S1473-3099(13)70162-2
Osinusi, Anuoluwapo, and Susanna Naggie. “Boceprevir for HCV in patients with HIV: where next?” Lancet Infect Dis 13, no. 7 (July 2013): 563–64. https://doi.org/10.1016/S1473-3099(13)70162-2.
Osinusi A, Naggie S. Boceprevir for HCV in patients with HIV: where next? Lancet Infect Dis. 2013 Jul;13(7):563–4.
Osinusi, Anuoluwapo, and Susanna Naggie. “Boceprevir for HCV in patients with HIV: where next?” Lancet Infect Dis, vol. 13, no. 7, July 2013, pp. 563–64. Pubmed, doi:10.1016/S1473-3099(13)70162-2.
Osinusi A, Naggie S. Boceprevir for HCV in patients with HIV: where next? Lancet Infect Dis. 2013 Jul;13(7):563–564.
Published In
Lancet Infect Dis
DOI
EISSN
1474-4457
Publication Date
July 2013
Volume
13
Issue
7
Start / End Page
563 / 564
Location
United States
Related Subject Headings
- Ribavirin
- Recombinant Proteins
- Proline
- Polyethylene Glycols
- Microbiology
- Male
- Interferon-alpha
- Interferon alpha-2
- Humans
- Hepatitis C, Chronic